Neurogene prices upsized stock offering, raises $134.8 million net

Neurogene Inc. entered into an underwriting agreement on June 30, 2026 with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC to sell 3,500,000 shares of common stock at a public offering price of $30.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 666,666 shares at $29.999999 per warrant.¹

The underwriters also received a 30-day option to buy up to 624,999 additional shares at the public offering price, less discounts and commissions, which the underwriters exercised in full on July 1, 2026.¹

The pre-funded warrants carry standard beneficial ownership caps: a holder cannot exercise if it would own more than 4.99% or 9.99% of outstanding shares, as applicable, though a holder can increase that limit up to 19.99% with at least 61 days' prior notice.¹

Neurogene expects net proceeds of approximately $134.8 million, after deducting underwriters' discounts and commissions and estimated offering expenses, including proceeds from the underwriters' full exercise of the option.¹

The shares were sold under an existing shelf registration, and the offering used a shelf registration statement, File No. 333-286057, that became effective on April 4, 2025.¹ The offering is expected to close on July 2, 2026.¹

Regarding use of the funds, the company said the net proceeds from the offering, combined with existing cash and cash equivalents, will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2029.¹